MGMT表达与非小细胞肺癌化疗疗效和预后关系的研究

MGMT expression and its relationship with efficacy of chemotherapy and prognosis in patients with non-small cell lung cancer

目的 研究MGMT在非小细胞肺癌 (NSCLC)组织中的表达情况及其与NSCLC患者化疗疗效和预后的关系。方法 应用免疫组化S P法检测正常肺组织及肿瘤组织中的MGMT表达。将 12 8例NSCLC组织分为Mer-组 (MGMT表达阴性 )和Mer+ 组 (MGMT表达阳性 )。结果 12 8例NSCLC中阳性表达率为 47.66% ( 61/ 12 8) ,而 10例正常肺组织中未见MGMT表达。MGMT表达与肺癌患者性别、年龄、肿瘤分期、淋巴结转移、组织类型等临床生理病理特征均无明显关系。Mer-组术后平均生存期及生存率均较Mer+ 组明显延长 (P <0 .0 1,P <0 .0 5 )。 45例可评价疗效的病例中 ,Mer-组总的化疗有效率为 42 .86% ( 9/2 1) ,Mer+ 组为 4.17% ( 1/ 2 4) (P <0 .0 0 1) ;Mer-组生存期和生存率明显高于Mer+ 组 (P <0 .0 1,P <0 .0 5 )。结论 MGMT表达水平可以作为临床预测NSCLC患者化疗疗效和预后的有意义的指标。

Objective To study the expression of MGMT and its relationship with efficacy of chemotherapy and prognosis in patients with non small cell lung cancer (NSCLC). Methods MGMT was detected in 128 NSCLC tissues and 10 normal pulmonary tissues by immunohistochemistry. According to the level of MGMT , 128 patients with NSCLC were divided into the group Mer - with negative MGMT expression and the group Mer + with positive MGMT expression. Results MGMT positively expressed in 61 of 128 patients with NSCLC (47.66%), but none of normal group. No significant relationship was found among MGMT expression and TNM stages, lymph node metastasis and histological classification of the cancer. However, the mean survival periods and survival rates in group Mer - were significantly higher than those of group Mer + (P< 0.01 , P<0.05). In 45 evaluable patients, total response rates were 42.86% and 4.17% in Mer - and Mer + patients respectively (P<0.001); and there were remarkably longer mean survival periods and higher survival rates in Mer - patients than those in Mer + patients (P<0.01, P<0.05). Conclusion Expression of MGMT may be helpful to predict efficacy of chemotherapy and prognosis in patients with NSCLC.